Value of Insulin-like Growth Factor II m-RNA-Binding Protein 3 (IMP3) Expression in Serous Ovarian Tumors: An immunohistochemical study | ||||
Zagazig University Medical Journal | ||||
Article 10, Volume 28, Issue 6.1, November 2022, Page 65-71 PDF (506.78 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/zumj.2020.22114.1678 | ||||
View on SCiNiTO | ||||
Authors | ||||
Reham Mostafa Elshahedy 1; Awatef Naguib Nasr2; Raafat Awad Hegazy3; Doaa Abdelaziz Ibrahim4 | ||||
1pathology department, faculty of medicine, Zagaig university | ||||
2pathology department, faculty of medicine, Zagazig university | ||||
3Pathology department, faculty of medicine, zagazig university | ||||
4pathology department, faculty of medicine, zagazig university | ||||
Abstract | ||||
Background: Ovarian cancer especially the epithelial type, is a major cause of female morbidity and mortality worldwide, so there is a great need for better diagnostic tools that can improve the histological diagnosis and predict the outcome by using immunohistochemical procedures. Aim of the work: To evaluate the immunohistochemical expression of Insulin-like Growth Factor II m-RNA-binding Protein 3 (IMP3) in benign, borderline and malignant serous ovarian tumors and correlate this expression with some clinicopathological parameters. Methods: This cross- sectional study was conducted retrospectively on 63 formalin fixed, paraffin embedded tissue blocks of serous ovarian tumors from pathology department, Zagazig University from 2016 to 2019. Immunohistochemical staining using anti- IMP3 antibodies was done using streptavidin-biotin immunoperoxidase technique. The relationship between the staining intensity and percentage of positively stained cells and clinicopathological factors were statistically analyzed. Results: IMP3 expression was detected in all borderline and 91.4% of malignant cases, 12.5% of benign cases. IMP3 intensity and percentage of positive stained cells were correlated with higher tumor grades and stages (P | ||||
Keywords | ||||
IMP3; SBTs; ovarian serous carcinomas; immunohistochemistry | ||||
Statistics Article View: 207 PDF Download: 67 |
||||